ACM
MLTX icon

ADAR1 Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

ADAR1 Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.52M Buy
+457,137
New +$7.57M 0.51% 48
2025
Q4 		– Sell
-151,495
Closed -$1.09M – 290
2025
Q3 		$1.09M Buy
151,495
+117,181
+341% +$6.11M 0.11% 98
2025
Q2 		$1.62M Buy
34,314
+28,890
+533% +$1.18M 0.26% 63
2025
Q1 		$212K Sell
5,424
-12,000
-69% -$517K 0.04% 145
2024
Q4 		$944K Sell
17,424
-6,033
-26% -$308K 0.19% 82
2024
Q3 		$1.18M Buy
23,457
+18,657
+389% +$874K 0.2% 62
2024
Q2 		$211K Buy
4,800
+1,800
+60% +$76.2K 0.04% 140
2024
Q1 		$151K Buy
+3,000
New +$163K 0.04% 132

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.43B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return